

Scientific publications based on Quality registry or knowledge of experts in NKCX

Publications in year 2023

- Accuracy of colposcopy in the Swedish screening program. *Acta Obstetrica et Gynecologica Scandinavica* n/a.
Alfonzo, E., Zhang, C., Daneshpaj, F., Strander, B., 2023.
- Assessing the risk of cervical neoplasia in the post-HPV vaccination era. *Int J Cancer* 152, 1060–1068.
Hu, K., Lehtinen, M., Pimenoff, V.N., Nedjai, B., Louvanto, K., Verhoef, L., Heideman, D.A.M., El-Zein, M., Widschwendter, M., Dillner, J., 2023.
- A review of data systems for assessing the impact of HPV vaccination in selected high-income countries. *Expert Rev Vaccines* 22, 161–179.
Wang, W.V., Kothari, S., Khoury, H., Niccolai, L., Garland, S.M., Sundström, K., de Pouvourville, G., Bonanni, P., Chen, Y.-T., Franco, E.L., 2023.
- Evaluation of co-testing with cytology and human papillomavirus testing in cervical screening. *Prev Med* 166, 107364.
Nordqvist Kleppe, S., Andersson, H., Elfström, K.M., Dillner, J., 2023.
- HPV-induced host epigenetic reprogramming is lost upon progression to high-grade cervical intraepithelial neoplasia. *International Journal of Cancer* 152, 2321–2330.
Herzog, C., Vavourakis, C.D., Barrett, J.E., Karbon, G., Villunger, A., Wang, J., Sundström, K., Dillner, J., Widschwendter, M., 2023a.
- Invasive cervical cancer, precancerous lesions, and cervical screening participation among women with mental illness in Sweden: a population-based observational study. *The Lancet Public Health* 8, e266–e275.
Hu, K., Wang, J., Sparén, P., Herweijer, E., Sjölander, A., Adami, H.-O., Valdimarsdóttir, U., Sundström, K., Fang, F., 2023.
- IPVS policy statement on HPV nucleic acid testing guidance for those utilising/considering HPV as primary precancer screening: Quality assurance and quality control issues. *Journal of Clinical Virology* 159, 105349.
Suzanne M. Garland a b c, Thomas Iftner d, Kate Cuschieri e f, Andreas M Kaufmann g, Marc Arbyn h, Silvia de Sanjose i, Mario Poljak j, Joakim Dillner k, Elizabeth R. Unger l on behalf of the IPVS Policy Committee.
- Quality assurance in human papillomavirus testing for primary cervical screening. *Int J Gynecol Cancer* ijgc–2022–004197.

Cuschieri, K., Fellner, M.D., Arroyo Mühr, L.S., Padalko, E., Correa, R.M., Dillner, J., Gultekin, M., Picconi, M.A., 2023.

Publications in year 2022

- Active expectancy as alternative to treatment for cervical intraepithelial neoplasia grade 2 in women aged 25 – 30 years: ExCIN2, a prospective clinical multicenter cohort study. *American Journal of Obstetrics and Gynecology*.
Kylebäck, K., Ekeryd-andalen, A., Greppe, C., Björkenfeldt havel, C., Zhang, C., Strander, B., 2022.
- Association of Chlamydia trachomatis infection with cervical atypia in adolescent women with short-term or long-term use of oral contraceptives: a longitudinal study in HPV vaccinated women. *BMJ Open* 12, e056824.
Adhikari, I., Eriksson, T., Harjula, K., Hokkanen, M., Apter, D., Nieminen, P., Luostarinen, T., Lehtinen, M., 2022.
- Associations between cervical intraepithelial neoplasia during pregnancy, previous excisional treatment, cone-length and preterm delivery: a register-based study from western Sweden
Johanna Wiik, Cecilia Kärrberg, Staffan Nilsson, Björn Strander, Bo Jacobsson & Verena Sengpiel , BMC Medicine volume 20, Article number: 61 (2022)
- A Simple Cervicovaginal Epigenetic Test for Screening
Herzog, C., Marín, F., Jones, A., Evans, I., Reisel, D., Redl, E., Schreiberhuber, L., Paytubi, S., Pelegrina, B., Carmona, Á., Peremiquel-Trillas, P., Frias-Gomez, J., Pineda, M., Brunet, J., Ponce, J., Matias-Guiu, X., de Sanjosé, S., Alemany, L., Olaitan, A., Wong, M., Jurkovic, D., Crosbie, E.J., Rosenthal, A.N., Bjørge, L., Zikan, M., Dostalek, L., Cibula, D., Sundström, K., Dillner, J., Costas, L., Widschwendter, M., 2022a.
- Atypical glandular cells and development of cervical cancer: Population-based cohort study. *Int J Cancer* 151, 2012–2019.
Norman, I., Yilmaz, E., Hjerpe, A., Hortlund, M., Elfström, K.M., Dillner, J., 2022.
- Colposcopic assessment by Swedescore, evaluation of effectiveness in the Swedish screening programme: a cross-sectional study. *BJOG: An International Journal of Obstetrics & Gynaecology* 129, 1261–1267.
Alfonzo, E., Holmberg, E., Milsom, I., Strander, B., 2022.
- Co-testing in cervical screening among 40- to 42-year-old women is unreasonable
Christer Borgfeldt, Anneli Leksell, Ola Forslund, 05 January 2022.
- DNA methylation-based detection and prediction of cervical intraepithelial neoplasia grade 3 and invasive cervical cancer with the WID™-qCIN test. *Clin Epigenetics* 14, 150.
Herzog, C., Sundström, K., Jones, A., Evans, I., Barrett, J.E., Wang, J., Redl, E., Schreiberhuber, L., Costas, L., Paytubi, S., Dostalek, L., Zikan, M., Cibula, D., Sroczyński, G., Siebert, U., Dillner, J., Widschwendter, M., 2022b.

- Effectiveness and costs of an implemented primary HPV cervical screening programme in Sweden – A population based cohort study
Bergengren, L., Ryen, L., Flodström, C., Fadl, H., Udumylen, R., Karlsson, M.G., Helenius, G., 2022
- Feasibility of sending a direct send HPV self-sampling kit to long-term non-attenders in an organized cervical screening program
Sahlgren, H., Sparén, P., Elfgrén, K., Elfström, K.M., 2022
- Head-to-head comparison of bi- and nonavalent human papillomavirus vaccine-induced antibody responses. *J Infect Dis* 324:190.
Mühr, L.S.A., Eklund, C., Lagheden, C., Eriksson, T., Pimenoff, V.N., Gray, P., Lehtinen, M., Dillner, J., 2022.
- Human Papillomavirus Infection Determines Prognosis in Cervical J Clin Oncol CO2101930.
Lei, J., Arroyo-Mühr, L.S., Lagheden, C., Eklund, C., Nordqvist Kleppe, S., Elfström, M., Andrae, B., Sparén, P., Dillner, J., Sundström, K., 2022.
- Human papillomavirus self-sampling with mRNA testing benefits routine screening. *Int J Cancer* 151, 1989–1996.
Auvinen, E., Nieminen, P., Pellinen, J., Dillner, J., Tarkkanen, J., Virtanen, A., 2022.
- Human Papillomavirus (HPV) seroprevalence, cervical HPV prevalence, genotype distribution and cytological lesions in solid organ transplant recipients and immunocompetent women in Sao Paulo, Brazil.
Miyaji, K.T., Infante, V., Picone, C. de M., Levi, J.E., Oliveira, A.C.S. de, Lara, A.N., Tacla, M., Dillner, J., Kann, H., Eklund, C., Castanheira, C.P., Mayaud, P., Sartori, A.M.C., Study group on HPV vaccine in immunosuppressed persons, 2022.
- Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial. *Lancet Glob Health* 10, e1473–e1484. Watson-Jones, D., Changalucha, J., Whitworth, H., Pinto, L., Mutani, P., Indangasi, J., Kemp, T., Hashim, R., Kamala, B., Wiggins, R., Songoro, T., Connor, N., Mbwangi, G., Pavon, M.A., Lowe, B., Mmbando, D., Kapiga, S., Mayaud, P., de SanJosé, S., Dillner, J., Hayes, R.J., Lacey, C.J., Baisley, K., 2022.
- Improving human papillomavirus (HPV) testing in the cervical cancer elimination era: The 2021 HPV LabNet international proficiency study. *J Clin Virol* 154, 105237
Arroyo Mühr, L.S., Eklund, C., Lagheden, C., Forslund, O., Robertsson, K.D., Dillner, J., 2022b.
- In 30 years, gender-neutral vaccination eradicates oncogenic human papillomavirus (HPV) types while screening eliminates HPV-associated cancers. *Expert Rev Vaccines* 21, 735–738.
Lehtinen, M., Gray, P., Louvanto, K., Vänskä, S., 2022.

- Overtreatment rate after immediate local excision of suspected cervical intraepithelial neoplasia: A prospective cohort study. *Gynecol Oncol* S0090-8258(22)01836-4.
Kiviharju, M., Heinonen, A., Jakobsson, M., Virtanen, S., Auvinen, E., Kotaniemi-Talonen, L., Dillner, J., Kyrgiou, M., Nieminen, P., Aro, K., Kalliala, I., 2022.
- Pregnancy Outcomes in Women With a Prior Cervical Intraepithelial Neoplasia Grade 3 Diagnosis. *Ann Intern Med* 175, 210–218.
He, W., Sparén, P., Fang, F., Sengpiel, V., Strander, B., Czene, K., 2022
- Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis. *BMJ* 378, e070135.
Kechagias, K.S., Kalliala, I., Bowden, S.J., Athanasiou, A., Paraskevaidi, M., Paraskevaidis, E., Dillner, J., Nieminen, P., Strander, B., Sasieni, P., Veroniki, A.A., Kyrgiou, M., 2022.
- Real-world impact and effectiveness of the quadrivalent HPV vaccine: an updated systematic literature review. *Expert Rev Vaccines* 21, 1799–1817
Wang, W.V., Kothari, S., Skufca, J., Giuliano, A.R., Sundström, K., Nygård, M., Koro, C., Baay, M., Verstraeten, T., Luxembourg, A., Saah, A.J., Garland, S.M., 2022.
- The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples
Barrett, J.E., Herzog, C., Jones, A., Leavy, O.C., Evans, I., Knapp, S., Reisel, D., Nazarenko, T., Kim, Y.-N., Franchi, D., Ryan, A., Franks, J., Bjørge, L., Zikan, M., Cibula, D., Harbeck, N., Colombo, N., Dudbridge, F., Jones, L., Sundström, K., Dillner, J., Rådestad, A.F., Gemzell-Danielsson, K., Pashayan, N., Widschwendter, M., 2022.
- The WID-CIN test identifies women with, and at risk of, cervical intraepithelial neoplasia grade 3 and invasive cervical cancer. *Genome Med* 14, 116.
Barrett, J.E., Sundström, K., Jones, A., Evans, I., Wang, J., Herzog, C., Dillner, J., Widschwendter, M., 2022b.

Time Trends for Incidence and Net Survival of Cervical Cancer in Sweden 1960-2014-A Nationwide Population-Based Study. *Cancer Epidemiol Biomarkers Prev* 31, 1572–1581.
Sundqvist, A., Moberg, L., Dickman, P.W., Högberg, T., Borgfeldt, C., 2022

Publications in year 2021:

- A dose-reduction HPV vaccine immunobridging trial of two HPV vaccines among adolescent girls in Tanzania (the DoRIS trial) - Study protocol for a randomised controlled trial. *Contemp Clin Trials* 101, 106266.
Baisley, K.J., Whitworth, H.S., Chagalucha, J., Pinto, L., Dillner J., Kapiga, S., de Sanjosé, S., Mayaud, P., Hayes, R.J., Lacey, C.J., Watson-Jones, D., 2021.
- Age, margin status, high-risk human papillomavirus and cytology independently predict recurrent high-grade cervical intraepithelial neoplasia up to 6 years after treatment. *Oncol Lett* 22, 684.

Andersson, S., Megyessi, D., Belkić, K., Alder, S., Östensson, E., Mints, M., 2021

- Associations of treated and untreated human papillomavirus infection with preterm delivery and neonatal mortality: A Swedish population-based study. *PLoS Med* 18, e1003641.
Wiik, J., Nilsson, S., Kärrberg, C., Strander, B., Jacobsson, B., Sengpiel, V., 2021.
- Audit of laboratory sensitivity of human papillomavirus and cytology testing in a cervical screening program
Maria Hortlund, Laila Sara Arroyo Mühr, Camilla Lagheden, Anders Hjerpe, Joakim Dillner
- Colposcopic assessment by Swedescore, evaluation of effectiveness in the Swedish screening programme: a cross-sectional study
Emilia Alfonso, Erik Holmberg, Ian Milsom, Björn Strander, 11 December 2021
- Cervical screening in high-income countries: the need for quality assurance, adjunct biomarkers and rational adaptation to HPV vaccination. *Prev Med* 144, 106382.
Sundström K., Herweijer E., Wang J., 2021.
- Comparison of cytology and human papillomavirus-based primary testing in cervical screening programs in the Nordic countries. *J Med Screen* 969141321992404
Partanen V.-M., Dillner J., Tropé A., Ágústsson Á.I., Pankakoski M., Heinävaara S., Sarkeala T., Wang J., Skare G.B., Anttila A., Lönnberg S., 2021.
- Determinants of Human Papillomavirus Vaccine Uptake by Adult Women Attending Cervical Cancer Screening in 9 European Countries. *Am J Prev Med* 60, 478–487.
Robles C., Bruni L., Acera A, Riera J.C., Prats L, Poljak M, Mlakar J, Oštrbenk Valenčak A, Eriksson T., Lehtinen M., Louvanto K., Hortlund M., Dillner J., Faber M.T., Munk C, Kjaer S.K., Petry K.U., Denecke A., Xu L., Arbyn M., Cadman L., Cuzick, J., Dalstein V., Clavel C., de Sanjosé S., Bosch F.X., 2021.
- Differing Age-Specific Cervical Cancer Incidence Between Different Types of Human Papillomavirus: Implications for Predicting the Impact of Elimination Programs *Am J Epidemiol* 2021 04;190(4):506-514.
- *Vänskä S, Luostarinen T, Lagheden C, Eklund C, Kleppe S, Andrae B, Sparén P, Sundström K, Lehtinen M, Dillner J*
- Distribution of HPV Genotypes Differs Depending on Behavioural Factors among Young Women. *Microorganisms* 9.
Bergqvist L, Kalliala I, Aro K, Auvinen E, Jakobsson M, Kiviharju M, Virtanen S, Dillner J., Nieminen P, Louvanto ., 2021.
- Equal prevalence of severe cervical dysplasia by HPV self-sampling and by midwife-collected samples for primary HPV screening: a randomised controlled trial. *Eur J Cancer Prev* 30, 334–340.

Hellsten C., Ernstson A., Bodelsson, G., Forslund, O., Borgfeld C., 2021.

- Exposure definition in case-control studies of cervical cancer screening: a systematic literature review. *Cancer Epidemiol Biomarkers Prev* cebp.0376.2021.
Castanon, A., Kaminen, A., Elfstrøm, K.M., Lim, A.W., Sasieni, P., 2021
- International Cancer Screening Network ICSN, 2021. Interruption of cancer screening services due to COVID-19 pandemic: lessons from previous disasters. *Prev Med Rep* 101399.
Puricelli Perin D.M., Christensen T., Burón A., Haas J.S., Kaminen A., Pashayan N., Rabeneck L., Smith R., Miriam Elfström, Mireille J.M. Broeders, for the International Cancer Screening Network ICSN
- HPV73 in cervical cancer and distribution of HPV73 variants in cervical dysplasia. *Int J Cancer*.
Borgfeldt C., Söderlund-Strand A., Flygh L.D., Forslund O., 2021.
- Human Papillomavirus Detection by Whole-Genome Next-Generation Sequencing: Importance of Validation and Quality Assurance Procedures. *Viruses* 13, 1323.
Arroyo Mühr LS, Guendiain D, Cuschieri C, Sundström K, 2021.
- Human Papillomavirus Load and Genotype Analysis Improves the Prediction of Invasive Cervical Cancer. *Int J Cancer*.
Hortlund M., van Mol, T., Van de Pol F., Bogers J.-P., Dillner J., 2021.
- Human papillomavirus seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland: A cross-sectional cohort analysis following a cluster randomized trial. *PLOS Med* 18, e1003588.
Gray P., Kann H., Pimenoff V.N., Eriksson T., Luostarinen T., Vänskä S., Surcel H., Faust H., Dillner J., Lehtinen M., 2021.
- Human papillomavirus vaccine efficacy against invasive, HPV-positive cancers: population-based follow-up of a cluster-randomised trial. *BMJ Open* 11, e050669
Matti Lehtinen, Camilla Lagheden, Tapio Luostarinen, Tiina Eriksson, Dan Apter, Anne Bly, Penelope Gray, Katja Harjula, Kaisa Heikkilä, Mari Hokkanen, Heidi Karttunen, Marjo Kuortti, Pekka Nieminen, Mervi Nummela, J Paavonen, Johanna Palmroth, Tiina Petäjä, Eero Pukkala, Anna Soderlund-Strand, Ulla Veivo, Joakim Dillner
- Nationwide Rereview of Normal Cervical Cytologies before High-Grade Cervical Lesions or before invasive Cervical Cancer. *Acta Cytologica* 2021;65:377–384
Edvardsson H., Wang J., Andrae B., Sparén P., Strander B., Dillner J., 2021 (online ahead of print).
- Non-vaccine HPV genotype common in women with HIV failing cervical precancer treatment. *AIDS*, 2021.
Carlander C., Lagheden C., Eklund C., Kleppe S., Dzabic M., Wagner P., Sparén P., Dillner J.

- Organized primary human papillomavirus–based cervical screening: A randomized healthcare policy trial.
Elfström M., Eklund C., Lamin H., Öhman D., Hortlund M., Elfgrén K., Sundström K., Dillner J.
Published: August 23, 2021.
- Promotion of Cervical Screening among Long-term Non-attendees by Human Papillomavirus Self-sampling. *J Cancer Prev* 26, 25–31.
Ernstson A., Forslund O., Borgfeld C., 2021.
- Prospects for accelerated elimination of cervical cancer
Dillner, J., Elfström, K.M., Baussano, I., 2021
- Real-world impact and effectiveness assessment of the quadrivalent HPV vaccine: a systematic review of study designs and data sources
Wang, W., Kothari, S., Baay, M., Garland, S.M., Giuliano, A.R., Nygård, M., Velicer, C., Tota, J., Sinha, A., Skufca, J., Verstraeten, T., Sundström, K., 2021.
- Self-sampling for high-risk human papillomavirus as a follow-up alternative after treatment of high-grade cervical intraepithelial neoplasia. *Oncol Lett* 21, 240.
Östensson, E., Belkić, K., Ramqvist, T., Mints, M., Andersson, S., 2021.
- The value of adding a single co-test in HPV primary screening
Jans, L., Zetterström, K., Bergengren, L., Helenius, G., 2021
- The 2019 HPV Labnet international proficiency study: Need of global Human Papillomavirus Proficiency Testing. *J Clin Virol* 141, 104902.
Eklund C., Mühr L.S.A., Lagheden C., Forslund O., Dahlin Robertsson K.D., Dillner J., 2021.
- Validation of the cobas 6800 human papillomavirus test in primary cervical screening
Sundström K., Lamin H., Dillner J., 2021.
- 2020 List of human papillomavirus assays Suitable for primary cervical cancer screening. *Clin Microbiol Infect.*
Arbyn M, Simon M, Peeters E, Meijer C.J.L.M., Berkhof J, Cuschieri K, Bonde J, Oštrbenk Valenčak, A, Zhao F-H, Rezhake R, Gultekin M, Dillner J., de Sanjosé S, Canfell K, Hillemanns P, Almonte M, Xu L, Wentzensen N, Poljak M, 2021. 2020

Publications in year 2020:

- Advances in cervical cancer prevention: Efficacy, effectiveness, elimination?
Sundström, K., Elfström, K.M., January 28, 2020. PLoS Med 17, e1003035.

- Baseline findings and safety of infrequent vs. frequent screening of human papillomavirus vaccinated women. *Int. J. Cancer* 147, 440–447.
Louvanto K, Eriksson, T., Gray P., Apter, D., Baussano, I., Bly, A., Harjula, K., Heikkilä, K., Hokkanen, M., Huhtinen, L., Ikonen, M., Karttunen, H., Nummela, M., Söderlund-Strand, A., Veivo, U., Dillner J., Elfström, M., Nieminen, P., Lehtinen M, 2020b.
- Colposcopic and histopathologic evaluation of women with HPV persistence exiting an organized screening program. *American Journal of Obstetrics and Gynecology* 222, 253.e1-253.e8.
Sahlgren, H., Elfström, K.M., Lamin, H., Carlsten-Thor, A., Eklund C, Dillner J., Elfgrén, K., 2020.
- Deep sequencing detects human papillomavirus (HPV) in cervical cancers negative for HPV by PCR.
Arroyo Mühr LS, Lagheden C, Lei J, Eklund C, Nordqvist Kleppe S, Sparén P, Sundström K, Dillner J *Br J Cancer* 2020 12;123(12):1790-1795
- Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries. *EClinicalMedicine* 23, 100401.
Kjaer S.K., Nygård, M., Sundström, K., Dillner J., Tryggvadóttir, L., Munk C, Berger, S., Enerly, E., Hortlund M, Ágústsson, Á.I., Bjelkenkrantz, K., Fridrich, K., Guðmundsdóttir, I., Sørbye, S.W., Bautista, O., Group, T., Luxembourg, A., Marshall, J.B., Radley, D., Yang, Y.S., Badshah, C., Saah, A., 2020.
- HPV Vaccination and the Risk of Invasive Cervical Cancer. *N Engl J Med* 383, 1340–1348.
Lei, J., Ploner, A., Elfström, K.M., Wang, J., Roth, A., Fang, F., Sundström, K., Dillner J., Sparén P., 2020.
- Human papillomavirus genotype-specific risks for cervical intraepithelial lesions. *Hum Vaccin Immunother* 1–10.
Nygård, M., Hansen, B.T., Kjaer S.K., Hortlund M, Tryggvadóttir, L., Munk C, Lagheden, C., Sigurdardóttir, L.G., Campbell, S., Liaw, K.-L., Dillner J., 2020.
- Human papillomavirus types in cervical dysplasia among young HPV-vaccinated women: Population-based nested case–control study. *International Journal of Cancer* 2020.
Kann H., Hortlund M, Eklund C, Dillner J., Faust, H., 2020
- Impact of HPV vaccination on cervical screening performance: a population-based cohort study. *Br J Cancer* 1–6.
Lei, J., Ploner, A., Lehtinen M, Sparén P., Dillner J., Elfström, K.M., 2020.
- Incomplete excision of cervical intraepithelial neoplasia as a predictor of the risk of recurrent disease—a 16-year follow-up study. *American Journal of Obstetrics and Gynecology* 222, 172.e1-172.e12.

Alder, S., Megyessi, D., Sundström, K., Östensson, E., Mints, M., Belkić, K., Arbyn M., Andersson, S., 2020.

- Increase of cervical cancer incidence in Sweden in relation to screening history: population cohort study. *Acta Oncologica* 59, 988–993.
Wang, J., Andrae, B., Strander, B., Sparén P., Dillner J., 2020.
- Key issues that need to be considered while revising the current annex of the European Council Recommendation (2003) on cancer screening. *Int. J. Cancer* 147, 9–13.
Ponti, A., Basu, P., Ritchie, D., Anttila, A., Carvalho, A.L., Senore, C., Mallafré-Larrosa, M., Piccinelli, C., Ronco, G., Soerjomataram, I., Primic-Žakelj, M., Dillner J., Elfström, M.K., Lönnberg, S., Vale, D.B., Tomatis, M., Armaroli, P., Giordano, L., Sankaranarayanan, R., Segnan, N., 2020.
- Long-term follow-up of human papillomavirus type replacement among young pregnant Finnish females before and after a community-randomised HPV vaccination trial with moderate coverage
Gray P., Kann H., Pimenoff V., Adhikari I., Eriksson T., Surcel H., Vänskä S., Dillner J., Faust H., Lehtinen M., First published: 23 June 2020
- Long-term effectiveness of the nine-valent human papillomavirus vaccine in Scandinavian women: interim analysis after 8 years of follow-up. *Hum Vaccin Immunother* 1–7.
Kjaer S.K., Nygård, M., Sundström, K., Munk C, Berger, S., Dzabic, M., Fridrich, K.E., Waldstrøm, M., Sørbye, S.W., Bautista, O., Group, T., Luxembourg, A., 2020.
- Methylation in Predicting Progression of Untreated High-grade Cervical Intraepithelial Neoplasia. *Clin Infect Dis* 70, 2582–2590.
Louvanto K, Aro, K., Nedjai, B., Bützow, R., Jakobsson, M., Kalliala, I., Dillner J., Nieminen, P., Lorincz, A., 2020a.
- Risk of Injuries around Diagnosis of Cervical Cancer and Its Precursor Lesions: A Nationwide Cohort Study in Sweden. *Cancer Epidemiol Biomarkers Prev* 29, 2230–2234.
Shen, Q., Lu, D., Andrae, B., Schelin, M.E.C., Sjölander, A., Cao, Y., Sparén P., Fang, F., 2020.
- Risk of vaginal cancer among hysterectomised women with cervical intraepithelial neoplasia: a population-based national cohort study. *BJOG International Journal of Obstetrics & Gynaecology* 127, 448–454.
Alfonzo, E., Holmberg, E., Sparén P., Milsom, I., Strander, B., 2020.
- Use of real-world data for HPV vaccine trial follow-up in the Nordic region. *Contemporary Clinical Trials* 92, 105996
Enerly, E., Berger, S., Kjær, S.K., Sundström, K., Campbell, S., Tryggvadóttir, L., Munk C, Hortlund M, Joshi, A., Saah, A.J., Nygård, M., 2020.
- Vaccination with Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied, *The Journal of Infectious Diseases*, 11 March 2020.

Vänskä S., Luostarinen T., Baussano I., Apter D., Tiina Eriksson G., Natunen K., Nieminen P., Paavonen J., Pimenoff V., Pukkala E., Söderlund-Strand A., Dubin G., Garnett G., Dillner J., Lehtinen M.

Publications in year 2019:

- Abnormal cervical cytology is associated with preterm delivery: a population based study. *Acta Obstet Gynecol Scand.*
Jar-Allah, T., Kärrberg, C., Wiik, J., Sengpiel, V., Strander, B., Holmberg, E., Strandell, A., 2019
- Age-specific HPV type distribution in high-grade cervical disease in screened and unvaccinated women. *Gynecologic Oncology* 154, 354–359.
Aro, K., Nieminen, P., Louvanto K, Jakobsson, M., Virtanen, S., Lehtinen M, Dillner J., Kalliala, I., 2019.
- Baseline findings and safety of infrequent vs. frequent screening of human papillomavirus vaccinated women
Louvanto, K., Eriksson, T., Gray, P., Apter, D., Baussano, I., Bly, A., Harjula, K., Heikkilä, K., Hokkanen, M., Huhtinen, L., Ikonen, M., Karttunen, H., Nummela, M., Söderlund-Strand, A., Veivo U., Dillner, J., Elfstöm, M., Nieminen, P., Lehtinen, M., First published: 20 November 2019
- Cancer Prevention Europe. *Mol Oncol.*
Wild, C.P., Espina, C., Bauld, L., Bonanni, B., Brenner, H., Brown, K., Dillner J., Forman, D., Kampman, E., Nilbert, M., Steindorf, K., Storm, H., Vineis, P., Baumann, M., Schüz, J., 2019.
- Cervical screening and risk of adenosquamous and rare histological types of invasive cervical carcinoma: population based nested case-control study. *BMJ* 365, l1207.
<https://doi.org/10.1136/bmj.l1207>
Lei, J., Andrae, B., Ploner, A., Lagheden, C., Eklund C, Kleppe, S.N., Wang, J., Fang, F., Dillner J., Elfström, K.M., Sparén P., 2019.
- Cervical cancer case-control audit: Results from routine evaluation of a nationwide cervical screening program. *International Journal of Cancer* 0.
Wang, J., Elfström, K.M., Andrae, B., Kleppe, S.N., Ploner, A., Lei, J., Dillner J., Sundström, K., Sparén P.
- Colposcopic and histopathologic evaluation of women with HPV persistence exiting an organized screening program. *American Journal of Obstetrics and Gynecology.*
Sahlgren, H., Elfström, K.M., Lamin, H., Carlsten-Thor, A., Eklund C, Dillner J., Elfgren, K., 2019.
- Contraceptive use at first intercourse is associated with subsequent sexual behaviors. *Contraception.*
Guleria, S., Thomsen, L.T., Munk C, Nygård, M., Hansen, B.T., Elfström, K.M., Arnheim-Dahlström, L., Liaw, K.-L., Frederiksen, K., Kjær, S.K., 2019.

- Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine. *Vaccine* 37, 2455–2462. Godi, A., Panwar, K., Haque, M., Cocuzza, C.E., Andrews, N., Southern, J., Turner, P., Miller, E., Beddows, S., 2019.
- Detection of HPV mRNA in Self-collected Vaginal Samples Among Women at 69-70 Years of Age. *Anticancer Res.* 39, 381–386. Ernstson A., Asciutto, K.C., Stuesson, J., Norén, J., Forslund, O., Borgfeld C., 2019.
- Eradication of human papilloma virus and elimination of HPV-related diseases - scientific basis for global public health policies. *Expert Rev Vaccines* 18, 153–160. Lehtinen M, Baussano, I., Paavonen, J., Vänskä, S., Dillner J., 2019.
- Early detection and prevention. *Mol Oncol* 13, 591–598. Dillner J., 2019a.
- HPV-mRNA and HPV-DNA detection in samples taken up to seven years before severe dysplasia of cervix uteri. *Int. J. Cancer* 144, 1073–1081. Forslund, O., Miriam Elfström, K., Lamin, H., Dillner J., 2019.
- Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study. *BMC Cancer* 19, 111 (2019). Egli-Gany, D., Spaar Zographos, A., Diebold, J., Masserey Spicher, V., Frey Tirri, B., Heusser, R., Dillner J., Petignat, P., Sahli, R., Low, N., CIN3+plus study group, 2019.
- Human papillomavirus types in cervical high-grade lesions or cancer among Nordic women- Potential for prevention. *Cancer Med*, First published: 11 January 2019 Cecilie Dovey de la Cour, Sonia Guleria , Mari Nygård , Laufey Trygvadóttir, Kristjan Sigurdsson, Kai-Li Liaw, Maria Hortlund, Camilla Lagheden, Bo T. Hansen , Christian Munk, Joakim Dillner , Susanne K. Kjaer
- Impact of the human papillomavirus status on the development of high-grade cervical intraepithelial neoplasia in women negative for intraepithelial lesions or malignancy at the baseline: A 9-year Swedish nested case-control follow-up study. *Cancer* 125, 239–248. Fröberg, M., Östensson, E., Belkić, K., Oštrbenk, A., Poljak, M., Mints, M., Arbyn M., Andersson, S., 2019.
- Increased HPV detection by the use of a pre-heating step on vaginal self samples analysed by Aptima HPV assay. *J. Virol. Methods* 270, 18–20. Borgfeld C., Forslund, O., 2019.
- Increasing participation in cervical screening by targeting long-term non-attenders: Randomized health services study. *Int. J. Cancer*.

Elfström, K.M., Sundström, K., Andersson, S., Bzhalava, Z., Carlsten Thor, A., Gzoul, Z., Öhman, D., Lamin, H., Eklund C, Dillner J., Törnberg, S., 2019.

- Long-term Antibody Response to Human Papillomavirus Vaccines: Up to 12 Years of Follow-up in the Finnish Maternity Cohort. *J. Infect. Dis.* 219, 582–589.
Artemchuk, H., Eriksson, T., Poljak, M., Surcel, H.-M., Dillner J., Lehtinen M, Faust, H., 2019.
- Participation in a Swedish cervical cancer screening program among women with psychiatric diagnoses: a population-based cohort study. *BMC Public Health* 19, 313.
Eriksson, E.M., Lau, M., Jönsson, C., Zhang, C., Risö Bergerlind, L.-L., Jonasson, J.M., Strander, B., 2019.
- Occurrence of human papillomavirus (HPV) type replacement by sexual risk-taking behaviour group: Post-hoc analysis of a community randomized clinical trial up to nine years after vaccination (IV). *Int. J. Cancer.*
Gray P., Luostarinen, T., Vänskä, S., Eriksson, T., Lagheden, C., Man, I., Palmroth, J., Pimenoff, V.N., Söderlund-Strand, A., Dillner J., Lehtinen M, 2019.
- Population-based primary HPV mRNA cervical screening compared with cytology screening. *Preventive Medicine* 124, 61–66
Lindroth, Y., Borgfeld C., Thorn, G., Bodelsson, G., Forslund, O., 2019.
- Methylation in predicting progression of untreated high-grade cervical intraepithelial neoplasia. *Clin. Infect. Dis.*
Louvanto K, Aro, K., Nedjai, B., Bützow, R., Jakobsson, M., Kalliala, I., Dillner J., Nieminen, P., Lorincz, A., 2019.
- Mode of HPV vaccination delivery and equity in vaccine uptake: A nationwide cohort study. *Prev Med* 120, 26– 33.
Wang, J., Ploner, A., Sparén P., Lepp, T., Roth, A., Arnheim-Dahlström, L., Sundström, K., 2019.
- NordScreen – an interactive tool for presenting cervical cancer screening indicators in the Nordic countries. *Acta Oncologica* 1–6.
Partanen, V.-M., Anttila, A., Heinävaara, S., Pankakoski, M., Sarkeala, T., Bzhalava, Z., Elfström, K.M., Tropé, A., Skare, G.B., Thorsteinsdóttir, S., Ágústsson, Á.I., Veerus, P., Koreinik, L., Dillner J., Lönnberg, S., 2019.
- Psychological distress is associated with cancer-specific mortality among patients with cervical cancer. *Cancer Res.*
Lu, D., Andrae, B., Valdimarsdóttir, U., Sundström, K., Fall, K., Sparén P., Fang, F., 2019.
- Response to the author: invitation to cancer screening: putting the car before the horse? *Eur. J. Cancer Prev.* 28, 458–459.

Vale, D.B., Anttila, A., Ponti, A., Senore, C., Sankaranaryanan, R., Ronco, G., Segnan, N., Tomatis, M., Žakelj, M.P., Elfström, K.M., Lönnberg, S., Dillner J., Basu, P., 2019

- Roadmap for a precision-medicine initiative in the Nordic region. *Nat Genet* 51, 924–930.
Njølstad, P.R., Andreassen, O.A., Brunak, S., Børglum, A.D., Dillner J., Esko, T., Franks, P.W., Freimer, N., Groop, L., Heimer, H., Hougaard, D.M., Hovig, E., Hveem, K., Jalanko, A., Kaprio, J., Knudsen, G.P., Melbye, M., Metspalu, A., Mortensen, P.B., Palmgren, J., Palotie, A., Reed, W., Stefánsson, H., Stitzel, N.O., Sullivan, P.F., Thorsteinsdóttir, U., Vaudel, M., Vuorio, E., Werge, T., Stoltenberg, C., Stefánsson, K., 2019.
- Sequencing detects human papillomavirus in some apparently HPV-negative invasive cervical cancers. *J. Gen. Virol.*
Arroyo Mühr, L.S., Lagheden, C., Eklund C, Lei, J., Nordqvist-Kleppe, S., Sparén P., Sundström, K., Dillner J., 2019.
- Seropositivity to Multiple Anogenital Human Papillomavirus (HPV) Types Is Associated With Current Anogenital HPV Infection, Abnormal Cytology, and Seropositivity for Nongenital HPVs. *J. Infect. Dis.* 219, 489–496.
Faust, H., Artemchuk, H., Oštrbenk, A., Triglav, T., Poljak, M., Dillner J., 2019.
- Some clear answers regarding transmission of genital human papillomavirus. *Lancet Infect Dis.*
Dillner J., 2019b.
- The Age-Specific Cervical Cancer Incidence Differs Between Human Papillomavirus Types: Implications for Predicting the Impact of Elimination Programs. *Am J Epidemiol.*
Vänskä, S., Luostarinen, T., Lagheden, C., Eklund C, Kleppe, S.N., Andrae, B., Sparén P., Sundström, K., Lehtinen M, Dillner J., n.d.
- The essential role of prevention in reducing the cancer burden in Europe: a commentary from Cancer Prevention Europe. *Tumori Journal* 030089161985186.
Espina, C., Bauld, L., Bonanni, B., Brenner, H., Brown, K., Dillner J., Kampman, E., Nilbert, M., Vineis, P., Weijenberg, M.P., Cox, A., de Kok, T.M., Fecht, D., Mitrou, G., Muller, D.C., Serrano, D., Steindorf, K., Storm, H., Thorat, M.A., van Duijnhoven, F., Weiderpass, E., Schüz, J., 2019.
- The HPV16 genome is stable in women who progress to in situ or invasive cervical cancer: a prospective population-based study. *Cancer Res.*
Arroyo-Mühr, L.-S., Lagheden, C., Hultin, E., Eklund C, Adami, H.-O., Dillner J., Sundström, K., 2019.

Publications in year 2018:

- Cervical cancer screening in Sweden 2014-2016. *PLoS ONE* 13, e0209003.
Hortlund M, Elfström, K.M., Sparén P., Almstedt, P., Strander, B., Dillner J., 2018.
- Colposcopy telemedicine: live versus static swede score and accuracy in detecting CIN2+, a cross-sectional pilot study. *BMC Womens Health* 18, 89.

Taghavi, K., Banerjee, D., Mandal, R., Kallner, H.K., Thorsell, M., Friis, T., Kocoska-Maras, L., Strander, B., Singer, A., Wikström, E., 2018.

- Continuing global improvement in human papillomavirus DNA genotyping services: The 2013 and 2014 HPV LabNet international proficiency studies. *J. Clin. Virol.* 101, 74–85.
Eklund C, Forslund, O., Wallin, K.-L., Dillner J., 2018.
- Costeffectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour. *Vaccine.*
Wolff, E., Elfström, K.M., Haugen Cange, H., Larsson, S., Englund, H., Sparén P., Roth, A., 2018.
- Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs. *Vaccine* 36, 3820–3829
Dillner J., Nygård, M., Munk C, Hortlund M, Hansen, B.T., Lagheden, C., Liaw, K.-L., Kjaer S.K., 2018
- Estimating effectiveness of HPV vaccination against HPV infection from post-vaccination data in the absence of baseline data. *Vaccine* 36, 3239–3246.
Vänskä, S., Söderlund-Strand, A., Uhnoo, I., Lehtinen M, Dillner J., 2018.
- Evaluation of HPV type-replacement in unvaccinated and vaccinated adolescent females Post-hoc analysis of a community-randomized clinical trial (II). *Int. J. Cancer* 142, 2491–2500.
Gray P., Palmroth, J., Luostarinen, T., Apter, D., Dubin, G., Garnett, G., Eriksson, T., Natunen, K., Merikukka, M., Pimenoff, V., Söderlund-Strand, A., Vänskä, S., Paavonen, J., Pukkala, E., Dillner J., Lehtinen M, 2018.
- Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomised trial (III). *Int. J. Cancer.*
Lehtinen M, Luostarinen, T., Vänskä, S., Söderlund-Strand, A., Eriksson, T., Natunen, K., Apter, D., Baussano, I., Harjula, K., Hokkanen, M., Kuortti, M., Palmroth, J., Petäjä, T., Pukkala, E., Rekonen, S., Siitari-Mattila, M., Surcel, H.-M., Tuomivaara, L., Paavonen, J., Nieminen, P., Dillner J., Dubin, G., Garnett, G., 2018.
- High-grade cervical intraepithelial neoplasia in human papillomavirus self-sampling of screening non-attenders. *Br. J. Cancer* 118, 138–144.
Lam, J.U.H., Elfström, K.M., Ejegod, D.M., Pedersen, H., Rygaard, C., Rebolj, M., Lynge, E., Juul, K.E., Kjær, S.K., Dillner J., Bonde, J., 2018.
- High-risk human papillomavirus status and prognosis in invasive cervical cancer: A nationwide cohort study. *PLOS Medicine* 15, e1002666.
Lei, J., Ploner, A., Lagheden, C., Eklund C, Kleppe, S.N., Andrae, B., Elfström, K.M., Dillner J., Sparén P., Sundström, K., 2018.
- Hpv-mrna and hpv-dna detection in samples taken up to seven years before severe dysplasia of cervix uteri. *International Journal of Cancer*, in press.
Forslund O, Lamin H, Elfström M and Dillner J.

- Human Papillomavirus Serology Among Women Living With HIV: Type-Specific Seroprevalence, Seroconversion, and Risk of Cervical Reinfection. *J. Infect. Dis.* Kelly, H., Faust, H., Chikandiwa, A., Ngou, J., Weiss, H.A., Segondy, M., Dillner J., Delany-Moretlwe, S., Mayaud, P., 2018.
- Human papillomavirus vaccination of adult women and risk of autoimmune and neurological diseases. *J. Intern. Med.* 283, 154–165. Hviid, A., Svanström, H., Scheller, N.M., Grönlund, O., Pasternak, B., Arnheim-Dahlström, L., 2018.
- ICTV Virus Taxonomy Profile: Papillomaviridae. *J. Gen. Virol.* 99, 989–990. Van Doorslaer, K., Chen, Z., Bernard, H.-U., Chan, P.K.S., DeSalle, R., Dillner J., Forslund, O., Haga, T., McBride, A.A., Villa, L.L., Burk, R.D., Ictv Report Consortium, null, 2018.
- Invitation strategies and coverage in the population-based cancer screening programmes in the European Union. *Eur. J. Cancer Prev.* Vale, D.B., Anttila, A., Ponti, A., Senore, C., Sankaranaryanan, R., Ronco, G., Segnan, N., Tomatis, M., Žakelj, M.P., Elfström, K.M., Lönnberg, S., Dillner J., Basu, P., 2018.
- Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development. *Vaccine.* Pinto, L.A., Dillner J., Beddows, S., Unger, E.R., 2018.
- Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I). *Int. J. Cancer* 142, 949–958. Lehtinen M, Söderlund-Strand, A., Vänskä, S., Luostarinen, T., Eriksson, T., Natunen, K., Apter, D., Baussano, I., Harjula, K., Hokkanen, M., Kuortti, M., Palmroth, J., Petäjä, T., Pukkala, E., Rekonen, S., Siitari-Mattila, M., Surcel, H.-M., Tuomivaara, L., Paavonen, J., Dillner J., Dubin, G., Garnett, G., 2018.
- Livmoderhalscancer ökar även hos kvinnor med normalt cellprov [Cervical cancer has increased in Sweden in women who had a normal cell sample]. *Läkartidningen* 115. Dillner J., Sparén P., Andrae, B., Strander, B., 2018.
- Nationwide comprehensive human papillomavirus (HPV) genotyping of invasive cervical cancer. *British Journal of Cancer* Lagheden, C., Eklund C, Lamin, H., Kleppe, S.N., Lei, J., Elfström, K.M., Sundström, K., Andrae, B., Sparén P., Dillner J., 2018.
- Opportunistic HPV vaccination at age 16-23 and cervical screening attendance in Sweden: a national register-based cohort study. *BMJ Open* 8, e024477. Kreusch, T., Wang, J., Sparén P., Sundström, K., 2018.
- Pedersen, K., Fogelberg, S., Thamsborg, L.H., Clements, M., Nygård, M., Kristiansen, I.S., Lynge, E., Sparén P., Kim, J.J., Burger, E.A., 2018.

An overview of cervical cancer epidemiology and prevention in Scandinavia. *Acta Obstet Gynecol Scand.*

- Prevalence of High-risk HPV in Postmenopausal Women with Benign Cervical Cytology - A Population-based Cohort Study. *Anticancer Res.* 38, 4221–4228.
Asciutto, K.C., Forslund, O., Borgfeld C., 2018b.
- Self-sampling with HPV mRNA analyses from vagina and urine compared with cervical samples. *J. Clin. Virol.* 101, 69–73. *Asciutto, K.C., Ernstson A., Forslund, O., Borgfeld C., 2018a.*
- Seroprevalences for 11 Human Papillomavirus (HPV) Types Mark Cumulative HPV Exposure. *J. Infect. Dis.*
Artemchuk, H., Triglav, T., Oštrbenk, A., Poljak, M., Dillner J., Faust, H., 2018.
- Socioeconomic and demographic determinants affecting participation in the Swedish cervical screening program: A population-based case-control study. *PLoS ONE* 13, e0190171.
Broberg, G., Wang, J., Östberg, A.-L., Adolfsson, A., Nemes, S., Sparén P., Strander, B., 2018.
- Status of implementation and organization of cancer screening in The European Union Member States Summary results from the second European screening report. *Int. J. Cancer* 142, 44–56.
Basu, P., Ponti, A., Anttila, A., Ronco, G., Senore, C., Vale, D.B., Segnan, N., Tomatis, M., Soerjomataram, I., Primic Žakelj, M., Dillner J., Elfström, K.M., Lönnberg, S., Sankaranarayanan, R., 2018.
- Substantially reduced incidence of genital warts in women and men six years after HPV vaccine availability in Sweden. *Vaccine* 36, 1917–1920.
Herweijer, E., Ploner, A., Sparén P., 2018.
- Suppressive antiretroviral therapy associates with effective treatment of high-grade cervical intraepithelial neoplasia. *AIDS.* 2018 May 8. *Christina Carlander, Philippe Wagner, Astrid van Beirs, Aylin Yilmaz, Kristina Elfgren, Joakim Dillner, Anders Sönnernborg, Pär Sparén*
- The Valgent4 protocol: Robust analytical and clinical validation of 11 HPV assays with genotyping on cervical samples collected in SurePath medium. *J. Clin. Virol.* 108, 64–71.
Bonde, J., Ejegod, D.M., Cuschieri, K., Dillner J., Heideman, D.A.M., Quint, W., Pavon Ribas, M.A., Padalko, E., Christiansen, I.K., Xu, L., Arbyn M., 2018.
- Towards quality and order in human papillomavirus research. *Virology* 519, 74–76.
Mühr L.S.A., Eklund C, Dillner J., 2018.

Publications in year 2017:

- A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries. *Clin. Infect. Dis.*

Kjaer S.K., Nygård, M., Dillner J., Brooke Marshall, J., Radley, D., Li, M., Munk C, Hansen, B.T., Sigurdardottir, L.G., Hortlund M, Tryggvadottir, L., Joshi, A., Das, R., Saah, A.J., 2017. A

- Different Challenges in Eliminating HPV16 Compared to Other Types: A Modeling Study. *J. Infect. Dis.* 216, 336–344.
Baussano, I., Lazzarato, F., Ronco, G., Lehtinen M, Dillner J., Franceschi, S., 2017.
- Effect of naturally acquired type-specific serum antibodies against human papillomavirus type 16 infection. *J. Clin. Virol.* 90, 64–69
Triglav, T., Artemchuk, H., Oštrbenk, A., Elfström, K.M., Faust, H., Poljak, M., Dillner J., 2017.
- Effectiveness of cervical screening after age 60 years according to screening history: Nationwide cohort study in Sweden. *PLoS Med.* 14, e1002414.
Wang, J., Andrae, B., Sundström, K., Ploner, A., Ström, P., Elfström, K.M., Dillner J., Sparén P., 2017.
- Human Papillomavirus (HPV) Prevalence in Male Adolescents 4 Years After HPV-16/18 Vaccination. *J. Infect. Dis.* 216, 966–968.
Lehtinen, T., Söderlund-Strand, A., Petäjä, T., Eriksson, T., Jokiranta, S., Natunen, K., Dillner J., Lehtinen M, 2017.
- Randomised healthcare policy evaluation of organised primary human papillomavirus screening of women aged 56-60. *BMJ Open* 7, e014788.
Lamin, H., Eklund C, Elfström, K.M., Carlsten-Thor, A., Hortlund M, Elfgren, K., Törnberg, S., Dillner J., 2017.
- Registry follow-up for 17 million person-years of a nationwide maternity cohort. *Cancer Med* 6, 3060–3064.
Lehtinen M, Surcel, H.-M., Natunen, K., Pukkala, E., Dillner J., 2017b. Cancer
- Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of three cohorts from randomized trials. *BMJ Open* 7, e015867.
Lehtinen M, Lagheden, C., Luostarinen, T., Eriksson, T., Apter, D., Harjula, K., Kuortti, M., Natunen, K., Palmroth, J., Petäjä, T., Pukkala, E., Siitari-Mattila, M., Struyf, F., Nieminen, P., Paavonen, J., Dubin, G., Dillner J., 2017a.
- Vaccination protects against invasive HPV-associated cancers. *Int. J. Cancer.*
Luostarinen, T., Apter, D., Dillner J., Eriksson, T., Harjula, K., Natunen, K., Paavonen, J., Pukkala, E., Lehtinen M, 2017.
- Risk of high-grade lesions after atypical glandular cells in cervical screening: a population-based cohort study. *BMJ Open* 7, e017070.
Norman, I., Hjerpe, A., Dillner J., 2017.

- Socio-economic and demographic determinants of participation in the Swedish cervical screening program: a population-based case-control study.
Broberg G, Wang J, Östberg A L, Adolfsson A., Nemes S, Sparén P, Strander B.
- Suppressive art associated with effective treatment of cervical precancer. Nordic HIV & Hepatitis Conference i Stockholm, 27-29 september 2017
Carlander C, Wagner P, van Beirs A, Yilmaz A, Elfgren K, Dillner J., Sönnernborg A, Sparén P
- The economic burden of human papillomavirus-related precancers and cancers in Sweden. PLoS ONE 12, e0179520.
Östensson, E., Silfverschiöld, M., Greiff, L., Asciutto, C., Wennerberg, J., Lydryp, M.-L., Håkansson, U., Sparén P., Borgfeld C., 2017.
- 2020 List of human papillomavirus assays Suitable for primary cervical cancer screening. Clin Microbiol Infect.
Arbyn M, Simon M, Peeters E, Meijer C.J.L.M., Berkhof J, Cuschieri K, Bonde J, Oštrbenk Valenčak, A, Zhao F-H, Rezhake R, Gultekin M, Dillner J., de Sanjosé S, Canfell K, Hillemanns P, Almonte M, Xu L, Wentzensen N, Poljak M, 2021. 2020